KETA.CN TripSitter Clinic Ltd. (CNQ) down 69% on 09 Feb 2026: watch cash runway

The KETA.CN stock price plunged 69.39% to C$0.15 in market hours on 09 Feb 2026. This sharp drop made TripSitter Clinic Ltd. one of today’s top losers on the CNQ exchange. The move followed heavy selling into a low-volume session of 1,500 shares traded. We examine cash metrics, valuation ratios, and short-term forecasts to explain the sell-off and what traders should watch next.

KETA.CN stock: intraday move and key price facts

TripSitter Clinic Ltd. (KETA.CN) opened at C$0.25 and hit a day low of C$0.15. The stock fell from a previous close of C$0.49, creating a C$0.34 one-day loss. Volume was 1,500 shares versus an average of 1,061, so the drop occurred on modest activity. The 50-day average price is C$0.10 and the 200-day average is C$0.08, showing recent volatility and a long downtrend.

KETA.CN stock fundamentals and financial ratios

TripSitter Clinic operates a telehealth platform for low-dose oral ketamine treatment and reports headquarters in Toronto, Canada. Key metrics show market cap C$998,726, shares outstanding 6,658,174, and EPS -0.04. Reported PE is -3.75 and book value per share is -0.12. The company shows negative operating cash flow per share of -0.01 and a current ratio close to 0.00, highlighting liquidity stress.

Meyka AI rates KETA.CN with a score out of 100 and technical view

Meyka AI rates KETA.CN with a score of 63.33 out of 100, Grade B, suggestion HOLD. This grade factors S&P 500 and sector comparisons, financial growth, key metrics, and analyst consensus. These grades are not guaranteed and we are not financial advisors.

On technicals the ADX reads 100.00 indicating a strong trend and RSI is at 0.00, consistent with a heavy one-day sell-off. Bollinger Bands show a middle band near C$0.06 and a lower band at C$0.03, which underlines elevated volatility.

KETA.CN stock valuation, forecasts and Meyka AI’s projections

Current price C$0.15 sits well below the 52-week high C$0.49 and above the 52-week low C$0.03. Meyka AI’s forecast model projects a monthly price of C$0.35 and a quarterly target of C$0.10. The monthly projection implies an upside of 133.33% from today’s price, while the quarterly projection implies a downside of -33.33%. Forecasts are model-based projections and not guarantees.

Risks, catalysts and sector context for KETA.CN stock

Major risks include tight liquidity, negative cash flow, and regulatory sensitivity in psychedelic therapies. TripSitter serves multiple U.S. states but has limited reported revenues and negative equity per share. The broader Healthcare sector is weaker year-to-date, increasing sector pressure. Catalysts would be published revenue growth, clearer cash runway, or licensing updates that reduce regulatory uncertainty.

Trading notes and strategy for top losers including KETA.CN stock

For traders, watch intraday volume above 5,000 to confirm sustained interest. Tight stop-losses are prudent given the one-day 69.39% swing. Longer-term investors should seek a clear revenue path and improved cash flow before adding exposure. Consider position sizing that limits exposure to micro-cap volatility and thin liquidity on the CNQ exchange.

Final Thoughts

KETA.CN stock collapsed 69.39% to C$0.15 on 09 Feb 2026, driven by heavy selling and thin volume. Fundamentals show negative EPS -0.04, negative book value -0.12 per share, and constrained liquidity with market cap C$998,726. Meyka AI’s forecast model projects a monthly price of C$0.35, implying 133.33% upside versus today’s price. That projection sits against a quarterly model target of C$0.10, which implies -33.33% downside. Given the grade of 63.33/100 (B, HOLD), investors should treat KETA.CN as speculative. Key next checks: cash runway, any updated earnings or revenue reports, and regulatory or licensing news in U.S. states served. Meyka AI provides this analysis as an AI-powered market analysis platform; forecasts are model-based projections and not guarantees.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.